DoctoriumGP
Body Composition Report
Jessica Gibson
29 March 2026
DoctoriumGP Body Composition Report — Scan 2 of 2
Jessica has been on tirzepatide since September 2025, currently at 10 mg (from a 15 mg pen, increased from 7.5 mg one month ago). Despite 6 months of treatment, there has been no meaningful weight loss — weight has increased by +0.2 kg, body fat has risen by +0.50%, and muscle mass has decreased by -0.30 kg. While there is room to increase the dose further, we first need to understand whether an underlying hormonal or metabolic issue is limiting the response. Increasing medication without addressing the root cause is unlikely to produce better results.
At 40.2%, Jessica carries more body fat than ~88% of UK women her age. The desirable range is 23–34%. This is the primary target for intervention.
52.5 kg of muscle mass is exceptional — higher than ~92% of UK women aged 30–39. This is a significant protective asset that must be preserved during any weight loss intervention.
A metabolic age of 51 vs chronological 36 places Jessica in the bottom 8%. Her body is functioning 15 years older than it should. This is the clearest signal that something is blocking normal metabolic function.
At 33.5, Jessica falls into Obese Class I. However, BMI alone is misleading here — her exceptional muscle mass inflates this figure. The body fat percentage and visceral fat rating give a more accurate clinical picture.
A rating of 8 is within the healthy range (1–12) but sits mid-table for women her age. Given the suspected PCOS and insulin resistance, targeted supplementation is recommended to bring this down — visceral fat is metabolically active and drives inflammation.
Scoring ~70 on the Tanita leg muscle scale places Jessica below average for her age. Despite strong overall muscle mass, lower body strength is a relative weakness — targeted lower body resistance training would improve this and support metabolic rate.
Jessica has been on tirzepatide since September 2025, currently at 10 mg (increased from 7.5 mg one month ago). Despite 6 months of treatment, there has been no meaningful weight loss — weight has increased slightly (+0.2 kg) and body fat percentage has risen (+0.50%). Muscle mass has slightly decreased (-0.30 kg).
While there is room to increase the dose, the priority is to first investigate whether an underlying condition is limiting the medication’s effectiveness. The Stride blood panel and methylation testing may reveal hormonal, metabolic, or cellular issues that need to be addressed before adjusting the dose. Increasing medication without understanding the root cause is unlikely to produce better results.
Clinical Director, DoctoriumGP • 29 March 2026
Based on the clinical picture — elevated triglycerides, lack of response to tirzepatide, visceral fat distribution, and weight loss failure despite 6 months of pharmacological intervention — there is a strong suspicion of underlying polycystic ovarian syndrome (PCOS).
PCOS commonly causes insulin resistance. If the body cannot process insulin effectively, this directly undermines how GLP-1 receptor agonists like tirzepatide work. The medication targets insulin pathways — if those pathways are already compromised, the drug cannot achieve its intended effect.
Visceral fat rating of 8, while within the healthy range, is elevated for someone on high-dose GLP-1 therapy. Targeted supplementation (inositol, berberine, omega-3, vitamin D, magnesium) may be needed to address the metabolic dysfunction that PCOS creates around visceral fat storage.
PCOS fundamentally alters how the body produces and uses energy. Mitochondrial function, glucose metabolism, and fat oxidation pathways are all affected. This explains why Jessica’s metabolic age is 15 years above her chronological age — her body is not burning fuel efficiently despite pharmacological support.
Jessica’s history of high cholesterol and statin use may be further compounding the problem. Statins can reduce the availability of steroid hormones (oestrogen, progesterone, testosterone, DHEA) because cholesterol is the precursor molecule for all steroid hormone production. This creates a secondary hormonal deficit on top of the PCOS-driven imbalance.
Comprehensive blood work to identify underlying hormonal and metabolic issues that may be blocking weight loss.
MTHFR and methylation panel to identify whether impaired methylation pathways are a key driver behind the metabolic resistance. If Jessica has PCOS combined with poor methylation, this creates a compounding effect where the body cannot properly:
This test will show us what Jessica’s body isn’t doing properly at a cellular level — and give us a targeted supplementation and lifestyle protocol to correct it.
Dr Gemma Lewis to review whether continuing tirzepatide at the current dose is appropriate given the suspected PCOS diagnosis. If insulin resistance is confirmed via blood panel, the tirzepatide may need to be combined with insulin-sensitising agents (e.g. metformin or inositol) rather than simply increasing or maintaining the GLP-1 dose. The underlying cause must be treated, not just the symptom.
Comprehensive assessment of current nutrition, sleep quality, stress levels, and physical activity patterns to identify modifiable factors that may be contributing to metabolic resistance.
Clinical input received: Dr Gemma Lewis MRCS MRCGP has reviewed this report and provided her clinical assessment (see Clinical Assessment section above). Further updates may follow once blood panel and methylation results are available.
Arrange comprehensive blood work to investigate hormonal and metabolic causes behind the lack of response to tirzepatide. Results expected within 5-7 working days.
Review blood panel results with Dr Gemma Lewis. Discuss findings and agree treatment plan adjustments based on identified metabolic blockers.
MTHFR and methylation pathway testing to assess whether impaired methylation is contributing to metabolic resistance and poor hormone clearance.
Full clinical review with Dr Gemma Lewis. Review all investigation results, reassess tirzepatide efficacy, and implement revised treatment protocol.
Repeat Tanita body composition scan 6-8 weeks following blood results and any protocol changes to assess whether the revised approach is producing measurable improvements.
Implement nutrition, sleep, and activity adjustments based on blood panel findings. Focus on supporting metabolic function and muscle preservation alongside any pharmacological changes.
| Segment | 6.25 kHz R/X | 50 kHz R/X | Phase Angle |
|---|---|---|---|
| Hand-to-Leg (H-L) | 772.2 / -45.4 | 662.6 / -77.9 | 6.74 |
| Right Leg (RL) | 321.7 / -21.7 | 275.2 / -31.7 | 6.60 |
| Left Leg (LL) | 351.8 / -22.6 | 303.6 / -35.5 | 5.57 |
| Right Hand (RH) | 422.9 / -27.5 | 367.2 / -41.9 | 6.54 |
| Left Hand (LH) | 405.9 / -28.1 | 349.0 / -40.6 | 6.67 |
| Leg-to-Leg (L-L) | 680.4 / -42.3 | 579.0 / -69.4 | 6.87 |